Evidence map›Paper›PMID 30943899›Full record

ArticleBMC gastroenterology2019

Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study.

Fotios S Fousekis, Konstantinos H Katsanos, Vasileios I Theopistos, Gerasimos Baltayiannis, Maria Kosmidou, Georgios Glantzounis, Leonidas Christou, Epameinondas V Tsianos, Dimitrios K Christodoulou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Mitochondrial Control in Inflammatory Gastrointestinal Diseases.International journal of molecular sciences · 2022
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Fotios S FousekisDepartment of Gastroenterology and Hepatology, Medical school and University of Ioannina, Ioannina, Greece.
Konstantinos H KatsanosDepartment of Gastroenterology and Hepatology, Medical school and University of Ioannina, Ioannina, Greece.
Vasileios I TheopistosDepartment of Gastroenterology and Hepatology, Medical school and University of Ioannina, Ioannina, Greece.
Gerasimos BaltayiannisDepartment of Gastroenterology and Hepatology, Medical school and University of Ioannina, Ioannina, Greece.
Maria KosmidouDepartment of Internal Medicine, Medical school and University of Ioannina, Ioannina, Greece.
Georgios GlantzounisDepartment of Surgery, Medical school and University of Ioannina, Ioannina, Greece.
Leonidas ChristouDepartment of Internal Medicine, Medical school and University of Ioannina, Ioannina, Greece.
Epameinondas V TsianosDepartment of Internal Medicine, Medical school and University of Ioannina, Ioannina, Greece.
Dimitrios K ChristodoulouDepartment of Gastroenterology and Hepatology, Medical school and University of Ioannina, Ioannina, Greece. dchristodoulou@gmail.com.ORCID http://orcid.org/0000-0001-9694-1160
University of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatobiliary and pancreatic manifestations have been reported in patients with Crohn's disease or ulcerative colitis. Our aim was to describe the prevalence of hepatobiliary and pancreatic manifestations in inflammatory bowel disease and their association with the disease itself and the medications used.

methodsData were retrospectively extracted from the clinical records of patients followed up at our tertiary IBD referral Center.

resultsOur study included 602 IBD patients, with liver function tests at regular intervals. The mean follow-up was 5.8 years (Std. Dev.: 6.72). Abdominal imaging examinations were present in 220 patients and revealed findings from the liver, biliary tract and pancreas in 55% of examined patients (120/220). The most frequent findings or manifestations from the liver, biliary tract and pancreas were fatty liver (20%, 44/220), cholelithiasis (14.5%, 32/220) and acute pancreatitis (0.6%, 4/602), respectively. There were 7 patients with primary sclerosing cholangitis. Regarding hepatitis viruses, one-third of the patients had been tested for hepatitis B and C. 5% (12/225) of them had positive hepatitis B surface antigen and 13.4% had past infection with hepatitis B virus (positive anti-HBcore). In addition, most of the patients were not immune against hepatitis B (negative anti-HBs), while 3% of patients were anti-HCV positive and only one patient had active hepatitis C. Furthermore, 24 patients had drug-related side effects from the liver and pancreas. The side effects included 21 cases of hepatotoxicity and 3 cases of acute pancreatitis. Moreover, there were two cases of HBV reactivation and one case of chronic hepatitis C, which were successfully treated.

conclusionIn our study, approximately one out of four patients had some kind by a hepatobiliary or pancreatic manifestation. Therefore, it is essential to monitor liver function at regular intervals and differential diagnosis should range from benign diseases and various drug related side effects to severe disorders, such as primary sclerosing cholangitis.

Indexed as

Acute DiseaseAdrenal Cortex HormonesAdultChemical and Drug Induced Liver InjuryCholangitis, SclerosingCholelithiasisColitis, UlcerativeCrohn DiseaseFatty LiverFemaleHepatitis BHepatitis CHumansImmunosuppressive AgentsLiver Function TestsMaleAdrenal Cortex HormonesImmunosuppressive AgentsAcute pancreatitisFatty liverHepatobiliary manifestationsHepatotoxicityImmunomodulatorsInflammatory bowel diseasePancreatic manifestations

Identifiers

PMID30943899
PMCPMC6446300
OpenAlexW2938320050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.